MMMarina C. Martinez

Marina C. Martinez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina C. Martinez has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Astero Klampatsa

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom

    2 shared publications
  • Edmund K. Moon

    Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine at the University of Pennsylvania

    2 shared publications
  • Edward Cantu

    Division of Cardiovascular Surgery, Perelman School of Medicine at the University of Pennsylvania

    2 shared publications
  • Evgeniy B. Eruslanov

    Division of Thoracic Surgery, Perelman School of Medicine at the University of Pennsylvania

    2 shared publications
  • Jeffrey C. Thompson

    Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine at the University of Pennsylvania

    2 shared publications
  • Steven M. Albelda

    Division of Pulmonary, Allergy, and Critical Care, Perelman School of Medicine at the University of Pennsylvania

    2 shared publications

Latest Publications

  • Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes

    by Astero Klampatsa, Shaun M. O’bRien, Jeffrey C. Thompson, Abhishek S. Rao, Jason E. Stadanlick, Marina C. Martinez, Maria Liousia, Edward Cantu, Keith Cengel, Edmund K. Moon, et al.

    Given the growing interest and promising preliminary results of immunotherapy in malignant pleural mesothelioma (MPM), it has become important to more fully understand the immune landscape in this tumor. This may be especially relevant in deciding who might benefit most from checkpoint blockade or agonist antibody therapy. Since the phenotype of tumor infiltrating lymphocytes (TILs) in MPM has not been fully described and their function has not been carefully assessed, we collected fresh tumor and blood from 22 patients undergoing surgical resection and analysed single cell suspensions by flow cytometry. The functionality of TILs was assessed by measurement of cytokine expression (IFN-γ) following overnight stimulation ex vivo. Results showed low numbers of CD8+ TILs whose function was either moderately or severely suppressed. The degree of TIL hypofunction did not correlate with the presence of co-existing macrophages or neutrophils, nor with expression of the inhibitory receptors PD-1, CD39 and CTLA-4. Hypofunction was associated with higher numbers of CD4 regulatory T cells (Tregs) and with expression of the inhibitory receptor TIGIT. On the other hand, presence of tissue-resident memory (Trm) cells and expression of TIM-3 on CD8+ cells were positively associated with cytokine production. However, Trm function was partially suppressed when the transcription factor Eomesodermin (Eomes) was co-expressed. Understanding the function of TILs in malignant mesothelioma may have clinical implications for immunotherapy, especially in choosing the best immunotherapy targets. Our data suggests that Treg cell blocking agents or TIGIT inhibitor antibodies might be especially valuable in these patients.


  • Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non–Small Cell Lung Cancer

    by Shaun M. O'BRien, Astero Klampatsa, Jeffrey C. Thompson, Marina C. Martinez, Wei-Ting Hwang, Abishek S. Rao, Jason E. Standalick, Soyeon Kim, Edward Cantu, Leslie A. Litzky, et al.

    Cancer progression is marked by dysfunctional tumor-infiltrating lymphocytes (TIL) with high inhibitory receptor (IR) expression. Because IR blockade has led to clinical responses in some patients with non–small cell lung cancer (NSCLC), we investigated how IRs influenced CD8+ TIL function from freshly digested early-stage NSCLC tissues using a killing assay and intracellular cytokine staining after in vitro T-cell restimulation. Early-stage lung cancer TIL function was heterogeneous with only about one third of patients showing decrements in cytokine production and lytic function. TIL hypofunction did not correlate with clinical factors, coexisting immune cells (macrophages, neutrophils, or CD4+ T regulatory cells), nor with PD-1, TIGIT, TIM-3, CD39, or CTLA-4 expression. Instead, we found that the presence of the integrin αeβ7 (CD103), characteristic of tissue-resident memory cells (TRM), was positively associated with cytokine production, whereas expression of the transcription factor Eomesodermin (Eomes) was negatively associated with TIL function. These data suggest that the functionality of CD8+ TILs from early-stage NSCLCs may be influenced by competition between an antitumor CD103+ TRM program and an exhaustion program marked by Eomes expression. Understanding the mechanisms of T-cell function in the progression of lung cancer may have clinical implications for immunotherapy.